This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Uresin, Y. Articles by Satlin, A. Search for Related Content PubMed PubMed Citation Articles by Uresin, Y. Articles by Satlin, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Diabetes Complications High Blood Pressure Social Bookmarking                         What's this?

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

Department of Pharmacology and Clinical Pharmacology, Istanbul Medical Faculty, Istanbul, Turkey, yagiz{at}istanbul.edu.tr

Addison A Taylor

Baylor College of Medicine, Houston, Texas, USA

Charles Kilo

Kilo Diabetes and Vascular Research Foundation-Washington University School of Medicine, St Louis, Missouri, USA

Diethelm Tschöpe

Ruhr-Universität Bochum, Bad Oeynhausen, Germany

Massimo Santonastaso

Unita Operativa di Medicina Generale, Ospedale Civile, Vittorio Veneto, Italy

Ghionul Ibram

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Hui Fang

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Andrew Satlin

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Objective. To assess the antihypertensive efficacy and safety of the combination of the direct renin inhibitor aliskiren and ramipril in patients with diabetes and hypertension.

Methods. In this double-blind, multicentre trial, 837 patients with diabetes mellitus and hypertension (mean sitting diastolic blood pressure [BP] > 95 and < 110 mmHg) were randomised to once-daily aliskiren (150 mg titrated to 300 mg after four weeks; n=282), ramipril (5 mg titrated to 10 mg; n=278) or the combination (n=277) for eight weeks. Efficacy variables were cuff mean sitting diastolic BP (msDBP) and mean sitting systolic BP (msSBP); 24-hour ambulatory BP, plasma renin activity (PRA) and plasma renin concentration (PRC) were also assessed.

Results. At week 8, aliskiren, ramipril and aliskiren/ramipril lowered msDBP (mean±SEM) by 11.3±0.5, 10.7±0.5 and 12.8±0.5 mmHg, and msSBP by 14.7±0.9, 12.0±0.9 and 16.6±0.9 mmHg, respectively. Aliskiren/ramipril provided superior msDBP reductions to ramipril (p=0.004) or aliskiren (p=0043) monotherapy; adding aliskiren to ramipril provided an additional mean BP reduction of 4.6/2.1 mmHg. Aliskiren monotherapy was non-inferior to ramipril for msDBP reduction (p=0.0002) and superior for msSBP reduction (p=0.021).All treatments significantly lowered mean 24-hour ambulatory BP. Aliskiren significantly reduced PRA from baseline as monotherapy (by 66%, p<0.0001) or in combination with ramipril (by 48%, p<0.0001), despite large increases in PRC in all treatment groups. Aliskiren was well tolerated as monotherapy or in combination with ramipril.

Conclusions. Combining aliskiren with ramipril provided a greater reduction in msDBP than either drug alone in patients with diabetes and hypertension.

Key Words: ambulatory blood pressure monitoring • diabetes mellitus • direct renin inhibitor • plasma renin activity

Journal of Renin-Angiotensin-Aldosterone System, Vol. 8, No. 4, 190-200 (2007)
DOI: 10.3317/jraas.2007.028


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Andersen, M. H Weinberger, C. M Constance, M. A Ali, J. Jin, M. F Prescott, and D. L Keefe Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension Journal of Renin-Angiotensin-Aldosterone System, September 1, 2009; 10(3): 157 - 167. [Abstract] [PDF]

				P. S Sever, A. H Gradman, and M. Azizi Managing cardiovascular and renal risk: the potential of direct renin inhibition Journal of Renin-Angiotensin-Aldosterone System, June 1, 2009; 10(2): 65 - 76. [Abstract] [PDF]

				D. S. Nuzum and T. Merz Macrovascular Complications of Diabetes Mellitus Journal of Pharmacy Practice, April 1, 2009; 22(2): 135 - 148. [Abstract] [PDF]

				T. Berl Review: Renal protection by inhibition of the renin-angiotensin-aldosterone system Journal of Renin-Angiotensin-Aldosterone System, March 1, 2009; 10(1): 1 - 8. [Abstract] [PDF]

				R. E. Schmieder, T. Philipp, J. Guerediaga, M. Gorostidi, B. Smith, N. Weissbach, M. Maboudian, J. Botha, and H. van Ingen Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren: A 12-Month Randomized, Double-Blind Comparator Trial With Hydrochlorothiazide Circulation, January 27, 2009; 119(3): 417 - 425. [Abstract] [Full Text] [PDF]

				{blacktriangledown}Aliskiren for hypertension in adults DTB, October 1, 2008; 46(10): 73 - 76. [Abstract] [Full Text] [PDF]

				R. Dietz, R. Dechend, C.-M. Yu, M. Bheda, J. Ford, M. F. Prescott, and D. L. Keefe Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1 Journal of Renin-Angiotensin-Aldosterone System, September 1, 2008; 9(3): 163 - 175. [Abstract] [PDF]

				M. J. Brown Aliskiren Circulation, August 12, 2008; 118(7): 773 - 784. [Abstract] [Full Text] [PDF]

				S. Ayalasomayajula, C.-M. Yeh, S. Vaidyanathan, B. Flannery, H. A. Dieterich, D. Howard, M. P. Bedigian, and W. P. Dole Effects of Aliskiren, a Direct Renin Inhibitor, on Cardiac Repolarization and Conduction in Healthy Subjects J. Clin. Pharmacol., July 1, 2008; 48(7): 799 - 811. [Abstract] [Full Text] [PDF]

				H.-H. Parving, F. Persson, J. B. Lewis, E. J. Lewis, N. K. Hollenberg, and the AVOID Study Investigators Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy N. Engl. J. Med., June 5, 2008; 358(23): 2433 - 2446. [Abstract] [Full Text] [PDF]

				J. R. Ingelfinger Aliskiren and Dual Therapy in Type 2 Diabetes Mellitus N. Engl. J. Med., June 5, 2008; 358(23): 2503 - 2505. [Full Text] [PDF]